Capsida Inc.

Analysis

Capsida Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 action is assigned to 1 distinct examiner and 1 distinct art unit. This indicates a highly targeted prosecution strategy, with all current active matters residing within a single technical specialty at the patent office. This concentration allows for a specialized approach but also means the company's immediate patent success is tied to a narrow administrative channel within the biotechnology department.

The busiest examiner for this portfolio is BANERJEE, KOYELI, who is responsible for 1 pending office action. Since there is only 1 pending action in total, this examiner manages the entirety of the company's active prosecution. For practitioners, this means that the immediate future of the company's patent portfolio is tied to the specific examination practices of this 1 examiner and the standards of the 1 art unit. Success in this matter will require a deep understanding of the specific examination style and previous rulings associated with this 1 official, as there are no other active matters to provide alternative paths to allowance. The strategy must be precisely aligned with the examiner's historical preferences to ensure a successful result.